{"nctId":"NCT02314637","briefTitle":"Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients","startDateStruct":{"date":"2009-08"},"conditions":["Type 2 Diabetes Mellitus"],"count":240,"armGroups":[{"label":"Teneligliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Teneligliptin"]},{"label":"Teneligliptin + Sulfonylurea","type":"EXPERIMENTAL","interventionNames":["Drug: Teneligliptin + Sulfonylurea"]}],"interventions":[{"name":"Teneligliptin","otherNames":[]},{"name":"Teneligliptin + Sulfonylurea","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* In case of combination therapy with Sulfonylurea, patients who has been receiving a stable dose and regimen of sulfonylurea for diabetes over 12 weeks before administration of investigational drug\n* Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug\n* HbA1c criteria:\n\n  * monotherapy: 6.9% - 10.5%\n  * combination therapy with Sulfonylurea: 7.4 - 10.5%\n* Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug.\n\nExclusion Criteria:\n\n* Patients with type 1 diabetes, diabetes mellitus caused by pancreas impairment, or secondary diabetes (Cushing disease, acromegaly, etc)\n* Patients who are accepting treatments of arrhythmias\n* Patients with serious diabetic complications\n* Patients who are the excessive alcohol addicts\n* Patients with severe hepatic disorder or severe renal disorder\n* Patients who are pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events","description":"Treatment-emergent adverse events (TEAE) were defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after receiving the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"136","spread":null},{"groupId":"OG001","value":"84","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c at Week 52","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.63","spread":"0.67"},{"groupId":"OG001","value":"-0.81","spread":"0.76"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose at Week 52","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.4","spread":"22.9"},{"groupId":"OG001","value":"-17.0","spread":"30.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":151},"commonTop":["Nasopharyngitis","Protein urine present","Glucose urine present","Blood creatine phosphokinase increased","Upper respiratory tract inflammation"]}}}